About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...
About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...
In non-small-cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) rearrangement treated with crizotinib, progression-free survival (PFS) varies according to the ALK fusion variant.
Brigatinib (Alunbrig) continued to prove its value as a promising first-line treatment for ALK-positive non-small cell lung cancer (NSCLC), according to a second interim analysis of the ALTA-1L trial.
Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...
AUSTIN, Texas, Oct. 28, 2025 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback